Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) today announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study show encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company.
The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, the process by which the protective myelin sheath around nerve fibers is damaged in multiple sclerosis. This imaging approach, if validated, could provide a non-invasive way to visualize myelin loss and repair in real time, potentially enhancing the development of MS therapies.
Quantum BioPharma believes the imaging data could support the development of its investigational candidate Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026.
"Reaching the halfway enrollment mark in this study is a meaningful milestone," said a company spokesperson. "The preliminary imaging signals we are seeing underscore the potential of this tracer to provide a clearer picture of demyelination activity, which could ultimately lead to better treatments for MS patients."
For more details on the press release, visit https://ibn.fm/4IZ0y.
The study is being conducted under a collaboration between Quantum BioPharma and Massachusetts General Hospital, a leading research institution. The ability to directly visualize demyelination could offer significant advantages over current imaging methods, which rely on indirect measures of tissue damage. Gray matter lesions, in particular, have been increasingly recognized as important contributors to disability in MS, but they are difficult to detect with conventional MRI.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing Lucid-MS as a potential disease-modifying therapy for multiple sclerosis. The company also holds a stake in Unbuzzd Wellness Inc., which markets an over-the-counter product for alcohol hangover relief, and retains royalty rights on sales of that product.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements.
For the latest news and updates on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM.
